Who mentions $VRTX most on Surfaced?

@adamfeuerstein (Adam Feuerstein ✡️) mentions $VRTX most — 11 mentions in the past 12 months.

When was $VRTX first mentioned on Surfaced?

The earliest tracked mention of $VRTX in the Surfaced archive was on Dec 6, 2025.

How many voices track $VRTX?

4 FinTwit voices have mentioned $VRTX 11 times in the past 12 months.

What kind of voices mention $VRTX most?

$VRTX is mentioned most by Biotech voices on Surfaced.

$VRTX — FinTwit mentions on Surfaced

Recent mentions

14 mentions

@adamfeuersteinJul 6, 2026 · 8:44 PM

$CRNX is a commercial stage biotech that was significantly underperforming the $XBI this year, similar to $INSM $MDGL $ALNY $BBIO Crinetics just acquired for a 100% premium by $VRTX. Unlike those other companies, it's stock also underperformed last year. Congrats to @Biohazard3737 - great call. Patience paid off.

Open on X

@adamfeuersteinJul 6, 2026 · 8:22 PM

$VRTX buying $CRNX $10B https://t.co/ikAEZdUjZw

Open on X

@acinvestorblogJul 5, 2026 · 3:26 PM

$VRTX Good breakout last week. Buyable on a pullback to the pivot. https://t.co/FqzfvDEfD2

Open on X

@adamfeuersteinJul 2, 2026 · 12:54 PM

Read here: A year after distressed buyout, what’s become of Bluebird Bio? CEO David Meek says the company, now called Genetix, is leading in sickle cell gene therapy $VRTX $CRSP $BEAM via @Jasonmmast https://t.co/PJcIWvMOcO

Open on X

@adamfeuersteinJul 2, 2026 · 12:54 PM

A year after distressed buyout, what’s become of Bluebird Bio? (Besides the new name, Genetix) Well... a lot, Genetix CEO David Meek told @Jasonmmast in a swaggering interview this week. Let me summarize Meek's proclamations: Genetix is profitable and on target to dominate the market for sickle cell gene therapies. "We’re the market leaders,” he said. “And our lead is just getting bigger," Meek said. $VRTX $CRSP Casgevy sucks, and the $BEAM effort is lame. “Let’s see if Beam even comes out, right? It’s a ghost right now,” he said. He offered no proof to back up the claims. Read more from Jason's interview with David Meek, link below.

Open on X

@investmentguru_Jul 1, 2026 · 11:38 PM

While AI continues to dominate headlines, Biotechnology is quietly becoming one of the strongest sectors in the market. Top 15 Biotechnology Stocks to Watch: $VRTX – Leader in cystic fibrosis treatments and expanding into gene-editing and rare diseases. $RVMD – Focused on precision oncology targeting RAS-driven cancers. $CRSP – Pioneer in gene-editing with approved and pipeline therapies. $NTLA – Developing in-vivo gene-editing treatments with breakthrough potential. $ABCL – AI-powered antibody discovery platform for drug development. $RXRX – Uses AI and automation to accelerate drug discovery at scale. $BEAM – Specializes in base-editing gene technology for precise DNA correction. $XENE – Focused on neurology and epilepsy-related treatments. $GH – Leader in liquid biopsy cancer diagnostics and early detection. $TWST – Produces synthetic DNA used in genomics and biotech research. $CGON – Developing immunotherapy treatments for bladder cancer and oncology. $DNLI – Focused on neurodegenerative diseases like Alzheimer’s and Parkinson’s. $IMVT – Developing therapies for autoimmune diseases using antibody technology. $ARWR – RNA interference platform targeting genetic and chronic diseases. $KRYS – Commercial-stage gene therapy company focused on rare skin disorders. These names represent the frontier of modern medicine where genetics, AI, and precision therapies are converging. As capital rotates beyond AI infrastructure, biotech is shaping up as one of the most compelling long-term opportunity sectors.

Open on X

@adamfeuersteinJun 4, 2026 · 8:01 PM

Otsuka kidney drug slowed loss of function, but less than expected, in late-stage trial. Results leave room for competing treatments from $VERA $VRTX to perform better https://t.co/EJWsEo5JEE

Open on X

@adamfeuersteinMar 12, 2026 · 4:41 PM

This week's Biotech Scorecard: Catching up on non-Prasad work. -- $ALDX is complaining about short sellers in the run-up to an FDA approval decision. Red flag! -- The $VRTX era of frictionless commerce is coming to an end. IgAN competition. -- $SRPT at a CEO crossroads. https://t.co/QIgn9e15Hd

Open on X

@adamfeuersteinMar 9, 2026 · 9:41 PM

Vertex $VRTX says its drug successfully reduced marker of kidney disease in late-stage trial https://t.co/TbEkcHVYBB via @Jasonmmast

Open on X

@kaizen_investorDec 22, 2025 · 9:18 PM

Biotech & Genomics is the 2nd largest growing TAM globally. Despite this potential, the sector remained stagnant in 2025. While capital flooded into AI, pharma was ignored. I expect this to change in 2026. Here are the companies on my watchlist: Metabolic & Weight Loss Leaders • $LLY (Eli Lilly): Obesity, diabetes, and Alzheimer's drugs • $NVO (Novo Nordisk): Global leader in diabetes care • $VKTX (Viking Therapeutics): Potent oral obesity therapies Surgical Robotics & Navigation • $ISRG (Intuitive Surgical): Robotic minimally invasive surgery • $PRCT (Procept BioRobotics): Robotic waterjet prostate surgery • $CLPT (ClearPoint Neuro): Precise navigation for brain surgery Gene Editing Pioneers • $NTLA (Intellia Therapeutics): In-vivo CRISPR gene editing • $BEAM (Beam Therapeutics): Precision genetic base editing • $PRME (Prime Medicine): Precise search-and-replace gene editing Diagnostic & Monitoring Tech • $DXCM (DexCom): Continuous glucose monitoring sensors • $NTRA (Natera): DNA testing for cancer/transplants • $WGS (GeneDx): Genomic diagnostics for rare diseases Specialized Biotech & Organ Care • $VRTX (Vertex): Cystic fibrosis and pain cures • $ARGX (Argenx): Novel autoimmune disease treatments • $TMDX (TransMedics): Living organ transport systems Bio-Infrastructure & Data • $VEEV (Veeva Systems): Cloud software for life sciences • $IQV (IQVIA): Clinical trial data and analytics • $TMO (Thermo Fisher): Scientific equipment and lab services • $DNA (Ginkgo Bioworks): Platform for cell programming Consumer Digital Health • $HIMS (Hims & Hers): Personalized telehealth and prescriptions

Open on X

@adamfeuersteinDec 6, 2025 · 9:09 PM

Hello! If you can break away from college football for a moment... #ASH25 Day One recap $SNDX Revuforj frontline AML results $VRTX $CRSP Casgevy in young kids Star Therapeutics - Von Willebrand disease Stand up for Science buttons and a brief STAT event recap https://t.co/in6RTsvyip via @statnews

Open on X

@adamfeuersteinAug 21, 2025 · 5:16 PM

@sharkbiotech $ALNY is safe (no risk of blowing up) + lots of growth = a biotech stock generalists can own without worry. It's why I called $ALNY the new $VRTX

Open on X

@adamfeuersteinAug 5, 2025 · 10:52 AM

From last night: Vertex $VRTX non-opioid pain franchise stumbles https://t.co/9rvPVrpBbC via @Jasonmmast @JonathanWosen

Open on X

@adamfeuersteinAug 4, 2025 · 8:25 PM

$VRTX tonight good test of how much investors care about the pain franchise bc looks troubled after these updates.

Open on X

$VRTX

$VRTX

About this stock

Frequently asked

Related stocks